Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IB-T101 injection to treat advanced clear renal cell carcinoma”In the company’s words, NCT06819293 on ClinicalTrials.gov
- Tested for
- Advanced Clear Renal Cell Carcinoma, Adult
- Main trialPhase 1
- “This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma”In the company’s words, NCT06819293 on ClinicalTrials.gov
Other drugs for Adult
- 5-Aminolevulinic Acid Hydrochloride PowderLee's Pharmaceutical Limited · Phase 3
- DordaviproneJazz Pharmaceuticals · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
Coming up1
- 7 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 7 Dec 2027 | IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026